<DOC>
	<DOCNO>NCT01518634</DOCNO>
	<brief_summary>The aim study test effect tricyclic antidepressant Imipramine patient longlasting health problem know medical explanation , define multi-organ Bodily distress syndrome ( BDS ) . Pharmacological treatment patient BDS never test , Imipramine low dosage ( 10-75 mg ) potential reduce pain symptom bodily distress patient BDS . Control condition pill placebo . Study duration 19 week 140 patient . End point 13 week , i.e . 10 week 25-75 mg study drug .</brief_summary>
	<brief_title>Imipramine Treatment Patients With Multi-organ Bodily Distress Syndrome</brief_title>
	<detailed_description>The aim study test effect Imipramine patient multi-organ Bodily distress syndrome ( BDS ) . BDS unifying diagnosis encompasses group closely related condition somatization disorder , fibromyalgia , irritable bowel syndrome chronic fatigue syndrome . The project consist double-blinded placebo control trial treatment tricyclic antidepressant Imipramine dosages 25-75 mg. Primary outcome patient-rated improvement measure Clinical Global Improvement Scale ( CGI-I ) . Secondary outcome functional level ( physical , mental social ) measure SF-36 Physical Component Summary ( PCS ) . The study require 140 participant study duration 19 week patient . End point 13 week , i.e . 10 week 25-75 mg study drug .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Imipramine</mesh_term>
	<criteria>1 . First time refer patient fulfil diagnostic criterion BDS multiorgan type symptoms 3 4 symptom category 2 . Moderate severe impact daily life 3 . Symptoms last least 2 year 4 . Age 2050 year 5 . Born Denmark Danish parent . The patient understands , speaks , write read Danish . 1 . Presence og physical psychiatric condition , symptoms condition clearly separate symptom BDS 2 . Current moderate severe depression , patient continuous antidepressant treatment moderate severe depression , patient severe psychiatric disorder demand treatment , patient suicidal . 3 . A lifetimediagnosis psychoses , mania depression psychotic symptom ( ICD10 : F2029 , F3031 , F32.3 , F33.3 ) 4 . Abuse alcohol , narcotic drug 5 . Pregnancy , breastfeed current pregnancy wish . Fertile woman must use effective anticonception , ( hormonal contraception , contraceptive injection , implant patch , intrauterine system device , vaginal ring ) . 6 . Treatment pain modulate drug , e.g . analgesic , antidepressant , antiepileptica type medication pain relieve property must discontinue least two week treatment phase . 7 . Imipramine treatment sufficient dosage within last year , i.e . 25 mg daily continuously least 8 week . 8 . Allergy study medication excipients study medication . 9 . Patients previous med myocardial infarction , congestive heart failure , sign conduction defect abnormality ECG ( first degree AVblock , bundle branch block prolong QTinterval ) , narrowangle glaucoma , porphyria , inherit galactose intolerance , epilepsy , hepatic insufficiency severe renal impairment 10 . Simultaneous use : antipsychotic oral anticoagulant diuretic sympathomimetics CNSstimulating drug ( amphetaminelike drug ) serotonergic drug , e.g . SSRI , SNRI TCA , dietary supplement hypericum perforatum , nonselective , irreversible selective , reversible monoamine oxidase ( MAO ) inhibitor , triptans , tramadol , pethidin tryptophan drug cimetidine ( H2antagonist ) , quinidine ( antiarrythmics ) , clonidine ( antihypertensive ) , fluconazol ( antimycotic ) , clindamycin , clarithromycin , erythromycin ( antibiotic ) , droperidol ( anaesthetic ) , levodopa ( antiparkinson ) , mefloquine ( antimalaria ) , phenytoin , barbiturate , carbamazepin ( antiepileptica ) Bupropion ( tobacco dependence ) , celecoxib ( NSAID ) , cinacalcet ( antiparathyroid drug ) , duloxetine ( SNRI ) , flufenazin ( antipsychotic ) , fluoxetin ( SSRI ) , gefitinib ( antineoplastic ) , moclobemid ( MAO ) , paroxetine , Sertraline ( SSRI ) , Terbinafine ( antimycotic ) , Yohimbin ( erectile dysfunction ) samt fluvoxamin ( SSRI ) , ciprofloxacin enoxacin ( microbiotic ) , plasma concentration Imipramine increase simultaneous use potent CYP2D6 CYP1A2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bodily Distress Syndrome</keyword>
	<keyword>Medically unexplained symptom</keyword>
	<keyword>Functional somatic symptom</keyword>
	<keyword>Functional somatic syndrome</keyword>
	<keyword>Treatment</keyword>
	<keyword>Imipramine</keyword>
	<keyword>Tricyclic antidepressant</keyword>
</DOC>